MX2017001869A - Formas cristalinas de un modulador de receptor de estrogeno. - Google Patents

Formas cristalinas de un modulador de receptor de estrogeno.

Info

Publication number
MX2017001869A
MX2017001869A MX2017001869A MX2017001869A MX2017001869A MX 2017001869 A MX2017001869 A MX 2017001869A MX 2017001869 A MX2017001869 A MX 2017001869A MX 2017001869 A MX2017001869 A MX 2017001869A MX 2017001869 A MX2017001869 A MX 2017001869A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
receptor modulator
crystalline forms
modulator
indazol
Prior art date
Application number
MX2017001869A
Other languages
English (en)
Inventor
D Smith Nicholas
R Herbert Mark
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017001869A publication Critical patent/MX2017001869A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En el presente documento se describen formas amorfas y cristalinas de sales farmaceuticamente aceptables del modulador de receptor de estrogeno acido (E)-3-(4-((E)-2-(2- cloro-4-fluorofenil)-1-(1H-indazol-5-il)but-1-en-1- il)fenil)acrilico. Tambien se describen composiciones farmaceuticas adecuadas para la administracion a un mamifero que incluyen el modulador de receptor de estrogeno, y metodos de uso del modulador de receptor de estrogeno, solo y en combinacion con otros compuestos, para tratar enfermedades o afecciones que estan asociadas con la actividad de receptor de estrogeno.
MX2017001869A 2014-08-11 2015-08-10 Formas cristalinas de un modulador de receptor de estrogeno. MX2017001869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462036015P 2014-08-11 2014-08-11
PCT/EP2015/068327 WO2016023847A1 (en) 2014-08-11 2015-08-10 Crystalline forms of an estrogen receptor modulator

Publications (1)

Publication Number Publication Date
MX2017001869A true MX2017001869A (es) 2017-05-17

Family

ID=54011696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001869A MX2017001869A (es) 2014-08-11 2015-08-10 Formas cristalinas de un modulador de receptor de estrogeno.

Country Status (15)

Country Link
US (1) US9783503B2 (es)
EP (1) EP3180316A1 (es)
JP (1) JP2017524009A (es)
KR (1) KR20170040251A (es)
CN (1) CN106660969A (es)
AR (1) AR101487A1 (es)
AU (1) AU2015303297A1 (es)
BR (1) BR112016029604A2 (es)
CA (1) CA2949329A1 (es)
IL (1) IL249160A0 (es)
MX (1) MX2017001869A (es)
RU (1) RU2017105840A (es)
SG (1) SG11201700995WA (es)
WO (1) WO2016023847A1 (es)
ZA (1) ZA201608000B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018533561A (ja) 2015-10-07 2018-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト （ｅ）−３−（４−（（ｅ）−２−（２−クロロ−４−フルオロフェニル）−１−（１ｈ−インダゾール−５−イル）ブタ−１−エン−１−イル）フェニル）アクリル酸を調製するためのプロセス
CN107973780B (zh) * 2016-10-21 2020-10-09 四川科伦博泰生物医药股份有限公司 一种取代的烯烃类化合物及其制备方法和用途
US20220017463A1 (en) * 2018-11-28 2022-01-20 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Salt Form of Estrogen Receptor Downregulator, Crystalline Form Thereof, and Preparation Method Therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667791A1 (en) * 2003-10-06 2006-06-14 Solvias AG Process for the parallel detection of crystalline forms of molecular solids
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9499538B2 (en) 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
MX2015011132A (es) 2013-03-14 2015-11-30 Seragon Pharmaceuticals Inc Moduladores policiclicos del receptor de estrogenos y sus usos.
KR20160085915A (ko) 2013-12-06 2016-07-18 에프. 호프만-라 로슈 아게 국소 진행성 또는 전이성 에스트로겐 수용체 양성 유방암을 치료하기 위한 에스트로겐 수용체 조절자
CA2941161A1 (en) 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
MA39741A (fr) 2014-03-13 2017-01-18 Hoffmann La Roche Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes

Also Published As

Publication number Publication date
KR20170040251A (ko) 2017-04-12
AR101487A1 (es) 2016-12-21
BR112016029604A2 (pt) 2017-08-22
CA2949329A1 (en) 2016-02-18
US9783503B2 (en) 2017-10-10
US20160039770A1 (en) 2016-02-11
JP2017524009A (ja) 2017-08-24
ZA201608000B (en) 2017-09-27
AU2015303297A1 (en) 2016-12-01
IL249160A0 (en) 2017-01-31
CN106660969A (zh) 2017-05-10
RU2017105840A (ru) 2018-09-13
WO2016023847A1 (en) 2016-02-18
EP3180316A1 (en) 2017-06-21
SG11201700995WA (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2018005620A (es) Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
EA033689B9 (ru) Ингибиторы g12c kras
NZ737399A (en) Ccr2 modulators
NZ732154A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12016502005A1 (en) Compounds and compositions for inducing chondrogenesis
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
NZ766530A (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
IN2015DN00885A (es)
PH12016500301A1 (en) Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
PH12017500089B1 (en) Aldosterone synthase inhibitors
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MX2017001869A (es) Formas cristalinas de un modulador de receptor de estrogeno.
TR201908151T4 (tr) İzoindolin türevleri.
MX2015012043A (es) Agonistas muscarinicos.
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
NZ731220A (en) Methods for treating kidney disorders
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
MA40553A (fr) Dérivés de pyrimidine substitués par un hétérocyclyle éventuellement condensés utiles pour le traitement des maladies inflammatoires, métaboliques, oncologiques et auto-immunes